Results 61 to 70 of about 38,022 (310)

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

Advanced Science, EarlyView.
This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre‐transplant dual therapy with GLP‐1 receptor agonists plus SGLT2 inhibitors is associated with post‐transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records ...
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Yen‐Liang Liu, Gideon Meyerowitz‐Katz, Tsung‐Hsun Tsai, Pen‐Hua Su   +7 more
wiley   +1 more source

A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias [PDF]

, 2017
Free Fatty Acid Receptor 2 is a GPCR activated by short chain fatty acids produced in high levels in the lower gut by microbial fermentation of non-digestible carbohydrates.
Aoki, Junken, Bolognini, Daniele, Hansen, Anders Højgaard, Hudson, Brian D., Inoue, Asuka, Kawakami, Kouki, Kishi, Takayuki, Milligan, Graeme, Sergeev, Eugenia, Ulven, Trond   +9 more
core   +3 more sources

Multimodal AI‐Driven Identification of Dehydrocostus Lactone as a Potent Renal Fibrosis Attenuator Targeting IQGAP1

Advanced Science, EarlyView.
Renal fibrosis, a hallmark of CKD, lacks effective treatments. Herein, we developed a multimodal AI model (TCM‐SPred) to identify anti‐fibrotic agents and found that dehydrocostus lactone (DCL) targets IQGAP1 to inhibit Wnt signaling, blocking the interaction between IQGAP1 and CCT3, demonstrating potent anti‐fibrotic activity in vitro and in vivo ...
Weijiang Lin, Wenzhuo Xu, Kang Liu, Ping Wang, Zhenzhen Zhu, Wenyu Lu, Zhe Zheng, Xiaoqian Peng, Xunkai Yin, Shulan Mei, An Pan, Jian Liu, Lihong Hu   +12 more
wiley   +1 more source

Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer

Frontiers in Pharmacology
Background: Glucagon-like peptide-1 (GLP-1) has crucial impact on glycemic control and weight loss physiologically. GLP-1 receptor agonists have been approved for treatment of diabetes and obesity.
Chaojun Zhu, Yihong Lai, Chengdong Liu, Lan Teng, Yuxin Zhu, Xinyu Lin, Xinyi Fu, Qiuhua Lai, Side Liu, Side Liu, Xiaohan Zhou, Yuxin Fang   +11 more
doaj   +1 more source

GLP-1 receptor agonists, carotid atherosclerosis and retinopathy [PDF]

Expert Opinion on Pharmacotherapy, 2017
It is known that diabetes is associated with the development of premature atherosclerosis and microvascular complications and consequently increased cardiovascular (CV) morbidity and mortality.
M. Rizzo, D. Nikolic, F. Di Pace, N. Papanas, N. Montano   +4 more
openaire   +3 more sources

Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics

Advanced Science, EarlyView.
This review provides a systematic comparison of extracellular vesicles (EVs) from both mammalian and plant sources in the context of autoimmune diseases. It highlights their emerging roles as precision biomarkers and engineered therapeutic platforms.
Yufei Wu, Huiyuan Ma, Tinghui Zhu, Shuwei Huang, Manxi Lu, Qiong Wang, Zai‐Long Chi   +6 more
wiley   +1 more source

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

Pharmaceuticals, 2022
Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes.
Lei Sun, Zhi-Ming Zheng, Chang-Sheng Shao, Zhi-Yong Zhang, Ming-Wei Li, Li Wang, Han Wang, Gen-Hai Zhao, Peng Wang   +8 more
doaj   +1 more source

Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]

, 2015
AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo, Dagostino, Mariangela Pia, Fallarino, Mara, Filardi, Tiziana, Lenzi, Andrea, Mandosi, Elisabetta, Morano, Susanna, Nieddu, Luciano, Romagnoli, Elisabetta, Turinese, Irene   +9 more
core   +1 more source

The complexity of dementia development and its comorbidities: The collaborative cross‐mouse population for multivarious tasks approach

Animal Models and Experimental Medicine, EarlyView.
The increasing prevalence of dementia and related neurodegenerative diseases—including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis—poses a growing public health challenge. These conditions have traditionally been studied as isolated central nervous system disorders, but emerging evidence points to ...
Osayd Zohud, Iqbal M. Lone, Kareem Midlej, Fuad A. Iraqi   +3 more
wiley   +1 more source

Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity

Obesity Facts, 2020
Objective: Hypothalamic obesity (HO) in children after treatment for a tumor in the suprasellar region has severe implications. Previous studies have shown various effects of glucagon-like peptide-1 (GLP-1) receptor agonist in acquired HO, but in adults ...
Jiska van Schaik, Dominique G.A. Begijn, Laura van Iersel, Yvonne Vergeer, Eelco W. Hoving, Babette Peeters, Hanneke M. van Santen   +6 more
doaj   +1 more source